Teleflex Incorporated (NYSE:TFX) was downgraded by equities research analysts at Deutsche Bank AG from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday. They presently have a $251.00 price target on the medical technology company’s stock. Deutsche Bank AG’s target price suggests a potential downside of 1.74% from the stock’s previous close.

Several other equities analysts have also weighed in on the stock. Piper Jaffray Companies began coverage on shares of Teleflex in a report on Friday, November 10th. They set an “overweight” rating and a $295.00 price objective on the stock. Morgan Stanley upped their price objective on shares of Teleflex from $274.00 to $290.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Jefferies Group LLC upped their price objective on shares of Teleflex from $270.00 to $295.00 and gave the company a “buy” rating in a report on Friday, November 3rd. Needham & Company LLC upped their price objective on shares of Teleflex from $237.00 to $285.00 and gave the company a “buy” rating in a report on Friday, November 3rd. Finally, Zacks Investment Research lowered shares of Teleflex from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $274.44.

Shares of Teleflex (NYSE:TFX) traded down $1.11 on Tuesday, reaching $255.44. 205,000 shares of the company’s stock were exchanged, compared to its average volume of 260,328. The company has a quick ratio of 3.70, a current ratio of 4.72 and a debt-to-equity ratio of 0.88. The company has a market capitalization of $11,557.39, a PE ratio of 31.71, a P/E/G ratio of 2.20 and a beta of 1.05. Teleflex has a twelve month low of $142.97 and a twelve month high of $263.97.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.12 EPS for the quarter, beating the Zacks’ consensus estimate of $2.01 by $0.11. Teleflex had a net margin of 12.41% and a return on equity of 16.27%. The business had revenue of $534.70 million for the quarter, compared to analysts’ expectations of $522.94 million. During the same quarter in the prior year, the firm posted $1.80 earnings per share. The business’s quarterly revenue was up 17.3% compared to the same quarter last year. research analysts forecast that Teleflex will post 8.34 EPS for the current fiscal year.

WARNING: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/11/16/teleflex-incorporated-tfx-rating-lowered-to-hold-at-deutsche-bank-ag.html.

In related news, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $237.18, for a total value of $47,436.00. Following the sale, the director now owns 8,080 shares in the company, valued at approximately $1,916,414.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 600 shares of company stock worth $138,162 in the last 90 days. 2.39% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the business. Federated Investors Inc. PA increased its stake in Teleflex by 65.4% in the 2nd quarter. Federated Investors Inc. PA now owns 38,160 shares of the medical technology company’s stock valued at $7,928,000 after buying an additional 15,091 shares during the last quarter. Legal & General Group Plc increased its stake in Teleflex by 25.6% in the 2nd quarter. Legal & General Group Plc now owns 85,403 shares of the medical technology company’s stock valued at $17,734,000 after buying an additional 17,403 shares during the last quarter. Clinton Group Inc. purchased a new stake in Teleflex in the 2nd quarter valued at about $325,000. Creative Planning increased its stake in Teleflex by 69.5% in the 2nd quarter. Creative Planning now owns 3,828 shares of the medical technology company’s stock valued at $795,000 after buying an additional 1,569 shares during the last quarter. Finally, Koch Industries Inc. increased its stake in Teleflex by 47,174.3% in the 2nd quarter. Koch Industries Inc. now owns 959,669 shares of the medical technology company’s stock valued at $955,000 after buying an additional 957,639 shares during the last quarter. Hedge funds and other institutional investors own 90.45% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Analyst Recommendations for Teleflex (NYSE:TFX)

Receive News & Stock Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related stocks with our FREE daily email newsletter.